Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Zocor Administered Earlier, At Higher Dose Following sNDA Approval

Executive Summary

Merck's Zocor can be administered earlier than other statins and at a higher starting dose following FDA approval of a supplemental NDA April 16

You may also be interested in...



Bristol Pravachol Ads Broaden Indication, FDA Warning Letter Says

FDA is asking Bristol-Myers Squibb to correct Pravachol advertising claims that the agency says broadens the indication and patient populations for which the cholesterol-lowering agent is approved

Zocor Rx Growth Picks Up In June; Merck Hopes Crestor Helps Revive Market

Zocor prescriptions appear to be picking up after a difficult first half for Merck's cholesterol lowering agent

Zocor Rx Growth Picks Up In June; Merck Hopes Crestor Helps Revive Market

Zocor prescriptions appear to be picking up after a difficult first half for Merck's cholesterol lowering agent

Related Content

UsernamePublicRestriction

Register

PS041657

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel